Published in J Virol on January 01, 2003
Chimpanzee adenovirus- and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults. Sci Transl Med (2015) 1.67
Pulmonary immunity and immunopathology: lessons from respiratory syncytial virus. Expert Rev Vaccines (2008) 1.23
Adults 65 years old and older have reduced numbers of functional memory T cells to respiratory syncytial virus fusion protein. Clin Vaccine Immunol (2012) 1.17
Identification of a common HLA-DP4-restricted T-cell epitope in the conserved region of the respiratory syncytial virus G protein. J Virol (2004) 0.93
RSV fusion (F) protein DNA vaccine provides partial protection against viral infection. Virus Res (2009) 0.89
Respiratory syncytial virus human experimental infection model: provenance, production, and sequence of low-passaged memphis-37 challenge virus. PLoS One (2014) 0.77
Neonatal calf infection with respiratory syncytial virus: drawing parallels to the disease in human infants. Viruses (2012) 0.77
Structural and Nonstructural Viral Proteins Are Targets of T-Helper Immune Response against Human Respiratory Syncytial Virus. Mol Cell Proteomics (2016) 0.75
Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol (1969) 10.85
An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol (1969) 6.85
Epidemiology of acute lower respiratory disease in children. N Engl J Med (1973) 5.58
Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am J Epidemiol (1969) 4.93
Determination of antigen-specific memory/effector CD4+ T cell frequencies by flow cytometry: evidence for a novel, antigen-specific homeostatic mechanism in HIV-associated immunodeficiency. J Clin Invest (1997) 4.01
Respiratory syncytial virus infection. Lancet (1999) 3.94
Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice. J Clin Invest (1991) 3.71
Respiratory syncytial viral infection in children with compromised immune function. N Engl J Med (1986) 3.43
Cytotoxic T cells clear virus but augment lung pathology in mice infected with respiratory syncytial virus. J Exp Med (1988) 3.39
Immunity to and frequency of reinfection with respiratory syncytial virus. J Infect Dis (1991) 3.27
Respiratory syncytial virus infection in adults. Clin Microbiol Rev (2000) 3.16
Distinct types of lung disease caused by functional subsets of antiviral T cells. J Exp Med (1994) 2.99
Altered peptide ligands can control CD4 T lymphocyte differentiation in vivo. J Exp Med (1995) 2.80
Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine. J Clin Microbiol (1986) 2.43
Virus-specific CD8+ T lymphocytes downregulate T helper cell type 2 cytokine secretion and pulmonary eosinophilia during experimental murine respiratory syncytial virus infection. J Exp Med (1997) 2.40
Pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of CD4+ T cells. J Virol (1992) 2.35
Pulmonary eosinophilic response to respiratory syncytial virus infection in mice sensitized to the major surface glycoprotein G. Int Immunol (1992) 2.25
Epidemiology of respiratory viral infection among paediatric inpatients over a six-year period in north-east England. Lancet (1978) 2.17
Human and murine cytotoxic T cells specific to respiratory syncytial virus recognize the viral nucleoprotein (N), but not the major glycoprotein (G), expressed by vaccinia virus recombinants. J Immunol (1986) 2.13
Cellular response to respiratory viruses with particular reference to children with disorders of cell-mediated immunity. J Pediatr (1980) 2.07
Cleavage of the human respiratory syncytial virus fusion protein at two distinct sites is required for activation of membrane fusion. Proc Natl Acad Sci U S A (2001) 2.04
Vaccine-enhanced respiratory syncytial virus disease in cotton rats following immunization with Lot 100 or a newly prepared reference vaccine. J Gen Virol (2001) 1.95
Respiratory syncytial virus infection in immunocompromised adults. Ann Intern Med (1988) 1.75
Immunopathology in RSV infection is mediated by a discrete oligoclonal subset of antigen-specific CD4(+) T cells. Immunity (2001) 1.69
CD4+ T cells clear virus but augment disease in mice infected with respiratory syncytial virus. Comparison with the effects of CD8+ T cells. Clin Exp Immunol (1992) 1.57
Proteolytic activation of respiratory syncytial virus fusion protein. Cleavage at two furin consensus sequences. J Biol Chem (2001) 1.55
Human cytotoxic T cells stimulated by antigen on dendritic cells recognize the N, SH, F, M, 22K, and 1b proteins of respiratory syncytial virus. J Virol (1992) 1.51
The attachment (G) glycoprotein of respiratory syncytial virus contains a single immunodominant epitope that elicits both Th1 and Th2 CD4+ T cell responses. J Immunol (2000) 1.50
Cytolytic T-lymphocyte responses to respiratory syncytial virus: effector cell phenotype and target proteins. J Virol (1990) 1.50
Virus-specific memory and effector T lymphocytes exhibit different cytokine responses to antigens during experimental murine respiratory syncytial virus infection. J Virol (1997) 1.48
Phenotypic and functional characterization of T cell lines specific for individual respiratory syncytial virus proteins. J Immunol (1993) 1.45
Relationship of serum antibody to risk of respiratory syncytial virus infection in elderly adults. J Infect Dis (1998) 1.34
Visualization and characterization of respiratory syncytial virus F-specific CD8(+) T cells during experimental virus infection. J Immunol (2001) 1.33
Demonstration of respiratory syncytial virus in an autopsy series. Pediatr Pathol (1990) 1.24
Distinct patterns of T- and B-cell immunity to respiratory syncytial virus induced by individual viral proteins. Vaccine (1993) 1.20
Respiratory syncytial virus infection in anti-mu-treated mice. J Virol (1991) 1.20
Mucosal delivery of a respiratory syncytial virus CTL peptide with enterotoxin-based adjuvants elicits protective, immunopathogenic, and immunoregulatory antiviral CD8+ T cell responses. J Immunol (2001) 1.17
Characterization of a novel respiratory syncytial virus-specific human cytotoxic T-lymphocyte epitope. J Virol (2000) 1.09
HLA class I-restricted cytotoxic T-cell epitopes of the respiratory syncytial virus fusion protein. J Virol (2000) 0.97
Eosinophilia at the time of respiratory syncytial virus bronchiolitis predicts childhood reactive airway disease. Pediatrics (2000) 0.91
Immunodominant T-cell epitope on the F protein of respiratory syncytial virus recognized by human lymphocytes. J Virol (1991) 0.90
Nucleotide sequence analysis of the bovine respiratory syncytial virus fusion protein mRNA and expression from a recombinant vaccinia virus. Virology (1991) 0.89
Different patterns of cytokine induction in cultures of respiratory syncytial (RS) virus-specific human TH cell lines following stimulation with RS virus and RS virus proteins. J Med Virol (1996) 0.88
HLA-DRB1,3,4,5 and -DQB1 allele frequencies and HLA-DR/DQ linkage disequilibrium of 231 German caucasoid patients and their corresponding 821 potential unrelated stem cell transplants. Hum Immunol (2000) 0.86
Recognition of respiratory syncytial (RS) virus proteins by human and BALB/C CD4+ lymphocytes. J Med Virol (1991) 0.85
Peripheral blood eosinophil counts and eosinophil cationic protein content of respiratory secretions in bronchiolitis: relationship to severity of disease. Pediatr Allergy Immunol (1994) 0.81
Identification of CD4+ T cell epitopes on the fusion (F) and attachment (G) proteins of bovine respiratory syncytial virus (BRSV). Vaccine (2001) 0.81
Respiratory syncytial virus and reactive airway disease. New developments prompt a new review. Am J Respir Crit Care Med (2001) 0.80
Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J Virol (2003) 11.48
Identification of formaldehyde-induced modifications in proteins: reactions with model peptides. J Biol Chem (2003) 2.60
Tolerogenic immune responses to novel T-cell epitopes from heat-shock protein 60 in juvenile idiopathic arthritis. Lancet (2005) 1.93
Correlate of immune protection against HSV-1 genital disease in vaccinated women. J Infect Dis (2013) 1.82
Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18-45 years. Hum Vaccin (2011) 1.46
H5N1 influenza vaccine formulated with AS03 A induces strong cross-reactive and polyfunctional CD4 T-cell responses. J Clin Immunol (2010) 1.36
CD8+ T cell responses in bronchoalveolar lavage fluid and peripheral blood mononuclear cells of infants with severe primary respiratory syncytial virus infections. J Immunol (2007) 1.26
Expanding the detectable HLA peptide repertoire using electron-transfer/higher-energy collision dissociation (EThcD). Proc Natl Acad Sci U S A (2014) 1.11
Regulatory T cells that recognize a ubiquitous stress-inducible self-antigen are long-lived suppressors of autoimmune arthritis. Proc Natl Acad Sci U S A (2012) 1.09
Dynamics of human respiratory virus-specific CD8+ T cell responses in blood and airways during episodes of common cold. J Immunol (2008) 1.06
Human CD8(+) T cell responses against five newly identified respiratory syncytial virus-derived epitopes. J Gen Virol (2004) 1.02
Intradermal fractional booster dose of inactivated poliomyelitis vaccine with a jet injector in healthy adults. Vaccine (2013) 1.02
Characterization of the CD8+ T cell responses directed against respiratory syncytial virus during primary and secondary infection in C57BL/6 mice. Virology (2006) 1.02
Synthesis of octa- and dodecamers of D-ribitol-1-phosphate and their protein conjugates. Carbohydr Res (2006) 1.01
Stable isotope tagging of epitopes: a highly selective strategy for the identification of major histocompatibility complex class I-associated peptides induced upon viral infection. Mol Cell Proteomics (2006) 0.99
Agonists of Toll-like receptors 3, 4, 7, and 9 are candidates for use as adjuvants in an outer membrane vaccine against Neisseria meningitidis serogroup B. Infect Immun (2007) 0.96
Resurgence of pertussis calls for re-evaluation of pertussis animal models. Expert Rev Vaccines (2012) 0.93
Differential effect of TLR2 and TLR4 on the immune response after immunization with a vaccine against Neisseria meningitidis or Bordetella pertussis. PLoS One (2010) 0.93
Epitope structure of the Bordetella pertussis protein P.69 pertactin, a major vaccine component and protective antigen. Infect Immun (2004) 0.90
Autoreactivity against induced or upregulated abundant self-peptides in HLA-A*0201 following measles virus infection. Hum Immunol (2003) 0.90
Immunogenicity of peptide-vaccine candidates predicted by molecular dynamics simulations. J Mol Biol (2003) 0.90
Immunodominance in mouse and human CD4+ T-cell responses specific for the Bordetella pertussis virulence factor P.69 pertactin. Infect Immun (2008) 0.89
Reactions of beta-propiolactone with nucleobase analogues, nucleosides, and peptides: implications for the inactivation of viruses. J Biol Chem (2011) 0.89
The killer immunoglobulin-like receptor (KIR) group A haplotype is associated with bronchiolitis obliterans syndrome after lung transplantation. J Heart Lung Transplant (2008) 0.89
Vigorous but short-term gamma interferon T-cell responses against a dominant HLA-A*02-restricted measles virus epitope in patients with measles. J Virol (2003) 0.88
Dynamics of measles virus protein expression are reflected in the MHC class I epitope display. Mol Immunol (2003) 0.87
The structure of Neisseria meningitidis lipid A determines outcome in experimental meningococcal disease. Infect Immun (2010) 0.87
Loss of antigen cross-presentation after complete tumor resection is associated with the generation of protective tumor-specific CD8(+) T-cell immunity. Oncoimmunology (2012) 0.87
Mass tag-assisted identification of naturally processed HLA class II-presented meningococcal peptides recognized by CD4+ T lymphocytes. J Immunol (2005) 0.86
Safety and immunogenicity of inactivated poliovirus vaccine based on Sabin strains with and without aluminum hydroxide: a phase I trial in healthy adults. Vaccine (2013) 0.86
No association between 12 dopaminergic genes and schizophrenia in a large Dutch sample. Am J Med Genet B Neuropsychiatr Genet (2005) 0.85
HLA and MICA associations with head and neck squamous cell carcinoma. Oral Oncol (2006) 0.84
HLA-DP4 presents an immunodominant peptide from the RSV G protein to CD4 T cells. Virology (2004) 0.84
Lung transplantation under a tacrolimus/mycophenolate mofetil-based immunosuppressive regimen results in low titers of HLA and MICA IgG antibodies which are not related to development of BOS. J Heart Lung Transplant (2010) 0.83
Children with celiac disease and high tTGA are genetically and phenotypically different. World J Gastroenterol (2013) 0.82
Bordetella pertussis proteins dominating the major histocompatibility complex class II-presented epitope repertoire in human monocyte-derived dendritic cells. Clin Vaccine Immunol (2014) 0.82
Crystal structure of an Anti-meningococcal subtype P1.4 PorA antibody provides basis for peptide-vaccine design. J Mol Biol (2005) 0.82
Chimerism of dendritic cell subsets in peripheral blood after lung transplantation. J Heart Lung Transplant (2011) 0.82
Pre-transplant soluble CD30 is associated with bronchiolitis obliterans syndrome after lung transplantation. J Heart Lung Transplant (2006) 0.82
Soluble CD30 measured after lung transplantation does not predict bronchiolitis obliterans syndrome in a tacrolimus/mycophenolate mofetil-based immunosuppressive regimen. J Heart Lung Transplant (2008) 0.80
Differential usefulness of biomarkers thymus and activation-regulated chemokine and soluble CD30 during enteric coated mycophenolate sodium and cyclosporine therapy in atopic dermatitis. J Am Acad Dermatol (2010) 0.79
Fast, antigen-saving multiplex immunoassay to determine levels and avidity of mouse serum antibodies to pertussis, diphtheria, and tetanus antigens. Clin Vaccine Immunol (2011) 0.79
Novel pan-DR-binding T cell epitopes of adenovirus induce pro-inflammatory cytokines and chemokines in healthy donors. Int Immunol (2006) 0.78
A cyclic undecamer peptide mimics a turn in folded Alzheimer amyloid β and elicits antibodies against oligomeric and fibrillar amyloid and plaques. PLoS One (2011) 0.78
Identification of HLA-A*0111N: a synonymous substitution, introducing an alternative splice site in exon 3, silenced the expression of an HLA-A allele. Hum Immunol (2005) 0.78
Hyperproliferation of B cells specific for a weakly immunogenic PorA in a meningococcal vaccine model. Clin Vaccine Immunol (2008) 0.78
Immunological and Fibrotic Mechanisms in Cardiac Allograft Vasculopathy. Transplantation (2015) 0.77
Gene therapy of mesothelioma. Expert Opin Biol Ther (2005) 0.76
Identifying the epitope-specific T cell response to virus infections. Vaccine (2007) 0.76
Impaired long-term maintenance and function of Bordetella pertussis specific B cell memory. Vaccine (2010) 0.76
The Induction of IgM and IgG Antibodies against HLA or MICA after Lung Transplantation. Pulm Med (2011) 0.75
Novel immunotherapy approaches to food allergy. Curr Opin Allergy Clin Immunol (2014) 0.75
Preparation of polysaccharide-conjugate vaccines. Methods Mol Med (2003) 0.75
Interference of daratumumab in monitoring multiple myeloma patients using serum immunofixation electrophoresis can be abrogated using the daratumumab IFE reflex assay (DIRA). Clin Chem Lab Med (2016) 0.75
Phacilitate, Barcelona Vaccine Forum 2010: focus on correlates of protection against influenza. Hum Vaccin (2010) 0.75
Clara cell secretory protein and surfactant protein-D do not predict bronchiolitis obliterans syndrome after lung transplantation. Transplantation (2010) 0.75